At the news
? NEUTRALIMPACT 2/10 DEFA14A filed Apr 24, 2026 at 16:06 ET
Immunome Inc. filed a definitive proxy statement (DEFA14A) for an upcoming shareholder meeting, which includes routine matters such as director elections and executive compensation. The filing is standard and does not contain any activist demands, merger proposals, or unexpected corporate actions. Market data shows recent insider selling activity, but no significant changes in analyst sentiment.
- Routine proxy filing for shareholder meeting
- No activist campaign or merger proposal
- Standard agenda items: director elections and executive compensation
- Recent insider selling of $1.6M vs $501K in buys
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access